Carregant...
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation
Ruxolitinib is a Janus kinase (JAK) inhibitor used for the treatment of myelofibrosis with demonstrated efficacy for the alleviation of disease-related symptoms and splenomegaly. Anemia and thrombocytopenia are the main secondary effects. However, there are case reports of rare but serious adverse e...
Guardat en:
| Publicat a: | Int J Hematol |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Japan
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7100122/ https://ncbi.nlm.nih.gov/pubmed/25034748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-014-1628-5 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|